Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography 2017 - 2022

  • ID: 4388394
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 4
The global antidepressants market is estimated to grow to approximately USD 13.4 billion by 2020, at a CAGR of 1.8%. Depression affects an estimated 121 million people worldwide and the antidepressant drug market reached sales of almost USD 11 billion in 2014.This study provides the market analysis for the major drug classes used for the treatment of depression.

Global Antidepressants Market-Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.

Drivers

An increasing number of people suffering from stress and increase in the awareness level of disease state and clinical needs are factors that drive the market.

Restraints

Poor efficacy and safety profiles, repeated drug failures in clinical trials, availability of generics and weak pipelines are the restraints faced by the market.

The market for antidepressants has been segmented based on the various classes of drugs that are generally used for the treatment of these psychiatric conditions. Various drug classes considered while estimating the overall market are selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCAs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), benzodiazepines, beta-blockers, atypical antipsychotics, and anticonvulsants. These drug classes cover major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD) and panic disorder (PD).

The report tells us about the symptoms, side effects and whether the drug is good for pregnant or breastfeeding women. The study says that biological differences, brain chemistry, hormones, inherited traits, etc. are the major causes of depression.

In terms of geography, the global antidepressants market has been categorized into four major regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Canadians are among the world's biggest users of antidepressants, with as much as 9% of the population on one depression-fighting drug or another. Like other countries, the use of antidepressants in the US has soared. In 1998, 11.2 million Americans used these drugs. By 2014, it was 23.3 million. Despite this rise, expenditure on antidepressants has barely risen as the drugs have become cheaper - from USD 624 per person in 1998 to USD 651 in 2014.

This Report Offers:

Market definition for the global antidepressants market along with identification of key drivers and restraints for the market.
Market analysis for the antidepressant market, with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Report description
1.2 Research methodology
2. Executive summary
3. Market overview
3.1 Market definition
3.2 Market drivers
3.2 1 Increasing number of patients
3.2.2 Increase in awareness level of disease state
3.2.3 Clinical needs pose a steady opportunity for growth of existing therapies
3.3 Market restraints
3.3.1 Poor efficacy and safety profiles restrain usage
3.3.2 Repeated drug failures in clinical trials
3.3.3 Availability of generics and weak pipelines
3.4 Market opportunities
3.5 Market threats
4. Porter’s five force analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market segmentation
5.1 By antidepressant therapies
5.1.1 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
5.1.2 Tricyclic Antidepressants (TCAs)
5.2 By depressive disorders
5.2.1 Obsessive-Compulsive Disorder (OCD)
5.2.2 Generalized Anxiety Disorder (GAD)
5.2.3 Panic Disorder (PD)
5.2 By treatments using patterns
5.2 1 Diseased population
5.2.2 Diagnosed population
5.2.3 Prescription population
5.3 By geography
5.3.1 North America
5.3.1.1 USA
5.3.1.2 Canada
5.3.2 Europe
5.3.2.1 France
5.3.2.2 United Kingdom
5.3.2.3 Germany
5.3.2.4 Spain
5.3.2.5 Italy
5.3.3 Asia-Pacific
5.3.3.1 Japan
6. Competitive landscape
6.1 Mergers and acquisitions
6.2 Collaborations, agreements, and partnerships
6.3 New product launches
6.4 Recommendations to new market players
7. Company profiles
7.1 H. Lundbeck
7.2 AstraZeneca
7.3 Eli Lilly and Company
7.4 Forest Laboratories
7.5 Pfizer Inc.
7.6 GlaxoSmithKline
7.7 Bristol-Myers Squibb Company
8. Appendix
8.1 Abbreviations
8.2 Sources
8.3 Bibliography
8.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll